GSK And Takeda Boost Arrowhead’s Coffers, But In-House Results Crucial To Gene Silencing Platform
Can RNAi Work In The Lung?
Executive Summary
Arrowhead is expecting a flurry of early-stage results from its in-house pipeline, including in lung diseases, where gene silencing platforms have so far struggled to reach, as it banks two recent milestone payments.
You may also be interested in...
Arrowhead Eager To Take On ‘Straightforward’ NASH Approach Abandoned By J&J
J&J pipeline review results in return of PNPLA3-targeted NASH candidate optioned under 2018 alliance, but the fate of a hepatitis B candidate included in that deal is undetermined so far.
Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage
Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.
Pfizer Will Struggle To Catch Novo Nordisk With Oral Obesity Treatments
Novo Nordisk reasserted its dominance in the GLP-1 agonist field this week, while Pfizer must hope that one of its two shots on goal is a success.